|
||||||||||||||||
HUM-MOLGEN -> Events -> Meetings and Conferences | ||||||||||||||||
Metabolic Diseases | ||||||||||||||||
March 04, 2002 | ||||||||||||||||
Park Hyatt at the Bellevue Hotel, Philadelphia May 6-7, 2002 ORGANIZED INTO THREE SECTIONS: - DISCOVERY & DRUG TARGET IDENTIFICATION - LEAD STRUCTURE IDENTIFICATION & CHARACTERIZATION - PRE-CLINICAL/CLINICAL DEVELOPMENT FEATURING: - Type 2 Diabetes Insulin Sensitizer - Leptin - Next Generation Diabetes Drug Targets - Thermogenesis - Antidiabetic Properties of GSK3 Inhibitors - PPAR-Gamma - Antisense Use in Diabetes - Transcription Factors - Insulin Resistance - Combination Therapy in Obesity - Mitochodrial Approaches - Functional Genomics |
||||||||||||||||
Organized by: | Strategic Research Institute | |||||||||||||||
Invited Speakers: | HIGHLIGHTS INCLUDE: Signaling Mechanism that Regulate Expression of UCP1 Sheila Collins, Ph.D., Duke University Medical Center Elucidation of Signaling Pathways and Transcription Stephen R. Farmer, M.D., Boston University School of Medicine Leptin as a Human Therapeutic Alex DePaoli, M.D., Amgen Inhibitors at New Allosteric Sites for Glycogen Phosphorylase & Fructose-1,6-Bisphosphatase Judith L. Treadway, Ph.D., Pfizer Global R & D - Groton Laboratories PRESENTATIONS BY: AGOURON PHARMACEUTICALS AMGEN BOSTON UNIVERSITY SCHOOL OF MEDICINE CHIRON CORPORATION DEVELOGEN AG DIGITAL GENE TECHNOLOGIES DUKE UNIVERSITY F. HOFFMAN-LA ROCHE GENEFORMATICS ISIS PHARMACEUTICALS LEXICON GENETICS MERCK RESEARCH LABS METABOLEX MITOKOR NOVO NORDISK PALATIN TECHNOLOGIES PFIZER GLOBAL R & D - GROTON LABS PFIZER GLOBAL R & D - LA JOLLA LABS REGENERON PHARMACETICALS |
|||||||||||||||
Deadline for Abstracts: | none | |||||||||||||||
Registration: | www.srinstitute.com/cs208 (212) 967-0095 |
|||||||||||||||
E-mail: | ckahan-radhuber@srinstitute.com | |||||||||||||||
Posted by: | Cheryl Kahan-Radhuber | |||||||||||||||
Host: | 12.3.58.15 | |||||||||||||||
|
||||||||||||||||
Generated by meetings and positions 5.0 by Kai Garlipp |